Evidence map›Paper›PMID 29380557›Full record

ArticleJournal of cachexia, sarcopenia and muscle2018

hmSOD1 gene mutation-induced disturbance in iron metabolism is mediated by impairment of Akt signalling pathway.

Malgorzata Halon-Golabek, Andzelika Borkowska, Jan J Kaczor, Wieslaw Ziolkowski, Damian J Flis, Narcyz Knap, Kajetan Kasperuk, Jedrzej Antosiewicz

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Malgorzata Halon-GolabekDepartment of Physiotherapy, Medical University of Gdansk, Gdansk, 80-211, Poland.
Andzelika BorkowskaDepartment of Bioenergetics and Physiology of Exercise, Medical University of Gdansk, Gdansk, 80-211, Poland.
Jan J KaczorDepartment of Bioenergetics and Physiology of Exercise, Medical University of Gdansk, Gdansk, 80-211, Poland.
Wieslaw ZiolkowskiDepartment of Bioenergetics and Nutrition, Gdansk University of Physical Education and Sport, Gdansk, 80-336, Poland.
Damian J FlisDepartment of Bioenergetics and Physiology of Exercise, Medical University of Gdansk, Gdansk, 80-211, Poland.
Narcyz KnapDepartment of Medical Chemistry, Medical University of Gdansk, Gdansk, 80-211, Poland.
Kajetan KasperukDepartment of Bioenergetics and Physiology of Exercise, Medical University of Gdansk, Gdansk, 80-211, Poland.
Jedrzej AntosiewiczDepartment of Bioenergetics and Physiology of Exercise, Medical University of Gdansk, Gdansk, 80-211, Poland.
Gdańsk Medical University · PLGdansk University of Physical Education and Sport · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, skeletal muscle atrophy, impairment of iron metabolism, and insulin signalling have been reported in rats suffering from amyotrophic lateral sclerosis (ALS). However, the interrelationship between these changes has not been studied. We hypothesize that an impaired Akt-FOXO3a signalling pathway triggers changes in the iron metabolism in the muscles of transgenic animals.

methodsIn the present study, we used transgenic rats bearing the G93A hmSOD1 gene and their non-transgenic littermates. The study was performed on the muscles taken from animals at three different stages of the disease: asymptomatic (ALS I), the onset of the disease (ALS II), and the terminal stage of the disease (ALS III). In order to study the molecular mechanism of changes in iron metabolism, we used SH-SY5Y and C2C12 cell lines stably transfected with pcDNA3.1, SOD1 WT and SOD1 G93A, or FOXO3a TM-ER.

resultsA significant decrease in P-Akt level and changes in iron metabolism were observed even in the group of ALS I animals. This was accompanied by an increase in the active form of FOXO3a, up-regulation of atrogin-1, and catalase. However, significant muscle atrophy was observed in ALS II animals. An increase in ferritin L and H was accompanied by a rise in PCBP1 and APP protein levels. In SH-SY5Y cells stably expressing SOD1 or SOD1 G93A, we observed elevated levels of ferritin L and H and non-haem iron. Interestingly, insulin treatment significantly down-regulated ferritin L and H proteins in the cell. Conversely, cells transfected with small interfering RNA against Akt 1, 2, 3, respectively, showed a significant increase in the ferritin and FOXO3a levels. In order to assess the role of FOXO3a in the ferritin expression, we constructed a line of SH-SY5Y cells that expressed a fusion protein made of FOXO3a fused at the C-terminus with the ligand-binding domain of the oestrogen receptor (TM-ER) being activated by 4-hydroxytamoxifen. Treatment of the cells with 4-hydroxytamoxifen significantly up-regulated ferritin L and H proteins level.

conclusionsOur data suggest that impairment of insulin signalling and iron metabolism in the skeletal muscle precedes muscle atrophy and is mediated by changes in Akt/FOXO3a signalling pathways.

Indexed as

Amyotrophic Lateral SclerosisAnimalsCell LineDisease Models, AnimalForkhead Box Protein O3HumansInsulinIronMaleMiceMuscle ProteinsMuscle, SkeletalMutationProto-Oncogene Proteins c-aktRats, Sprague-DawleyRats, TransgenicFbxo32 protein, ratForkhead Box Protein O3FOXO3 protein, ratInsulinIronMuscle ProteinsProto-Oncogene Proteins c-aktSKP Cullin F-Box Protein LigasesSOD1 protein, humanSuperoxide Dismutase-1ALSFerritinFOXO3aMuscle iron metabolismOxidative stressp66Shc

Identifiers

PMID29380557
PMCPMC5989766
OpenAlexW2790761799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.